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Computational Resource, La Jolla, CaliforniaABSTRACT Protein kinase A (PKA) phosphorylation of myofibril proteins constitutes an important pathway for b-adrenergic
modulation of cardiac contractility and relaxation. PKA targets the N-terminus (Ser-23/24) of cardiac troponin I (cTnI), cardiac
myosin-binding protein C (cMyBP-C) and titin. The effect of PKA-mediated phosphorylation on the magnitude of contraction
has been studied in some detail, but little is known about how it modulates the kinetics of thin filament activation and myofibril
relaxation as Ca2þ levels vary. Troponin C (cTnC) interaction with cTnI (C-I interaction) is a critical step in contractile activation
that can be modulated by cTnI phosphorylation. We tested the hypothesis that altering C-I interactions by PKA, or by cTnI
phosphomimetic mutations (S23D/S24D-cTnI), directly affects thin filament activation and myofilament relaxation kinetics. Rat
ventricular myofibrils were isolated and endogenous cTn was exchanged with either wild-type cTnI, or S23D/S24D-cTnI
recombinant cTn. Contractile mechanics were monitored at maximum and submaximal Ca2þ concentrations. PKA treatment
of wild-type cTn or exchange of cTn containing S23D/S24D-cTnI resulted in an increase in the rate of early, slow phase of
relaxation (kREL,slow) and a decrease in its duration (tREL,slow). These effects were greater for submaximal Ca
2þ activated contrac-
tions. PKA treatment also reduced the rate of contractile activation (kACT) at maximal, but not submaximal Ca
2þ, and reduced the
Ca2þ sensitivity of contraction. Using a fluorescent probe coupled to cTnC (C35S-IANBD), the Ca2þ-cTn binding affinity and C-I
interaction were monitored. Ca2þ binding to cTn (pCa50) was significantly decreased when cTnI was phosphorylated by PKA
(DpCa50 ¼ 0.31). PKA phosphorylation of cTnI also weakened C-I interaction in the presence of Ca2þ. These data suggest
that weakened C-I interaction, via PKA phosphorylation of cTnI, may slow thin filament activation and result in increased myofil-
ament relaxation kinetics, the latter of which could enhance early phase diastolic relaxation during b-adrenergic stimulation.INTRODUCTIONCardiac muscle contractile activation is initiated by Ca2þ
binding to troponin C (cTnC) and a subsequent increased
interaction with troponin I (cTnI), leading to increased
tropomyosin mobility and myosin interaction with actin
(1). Relaxation ensues as Ca2þ is released from cTnC and
is pumped back into the sarcoplasmic reticulum, resulting
in reestablishment of cross-bridge inhibition via tropomy-
osin-mediated steric blocking as myosins detach from the
thin filament (2). We (3–8) and others (9,10) have demon-
strated that Ca2þ binding to cardiac troponin C (cTnC)
is less effective than Ca2þ binding to skeletal TnC in
activating contraction, primarily due to weaker affinity of
N-terminal Ca2þ binding and a weaker affinity (KC-I) of
Ca2þ-cTnC for the switch domain of cTnI. This suggests
cTnC-cTnI (C-I) interaction as a potential point for modu-
lation in the thin filament activation pathway to regulate sys-
tolic performance at rest (basal activity) and particularly
during b-adrenergic stimulation. cTnI, along with cardiacSubmitted March 6, 2014, and accepted for publication July 15, 2014.
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ment protein targets for phosphorylation by b-adrenergic
stimulation (11–14).
For cTnI, b-adrenergic stimulation results in phosphory-
lation of Ser-23 and -24 by protein kinase A (PKA). Phos-
phorylation at these sites has been shown to reduce C-I
interaction strength (15), reduce the Ca2þ sensitivity
(pCa50) of cardiac muscle tension production (11), increase
cross-bridge cycling kinetics, and accelerate cardiac muscle
cell relaxation (11,12). However, little is known about how
PKA phosphorylation of cTnI modulates the kinetics of
thin filament activation or myofibril relaxation, and how
this kinetic modulation may be affected with changing
Ca2þ levels that occur during b-adrenergic stimulation.
In this study, we tested the hypothesis that PKA phos-
phorylation of cTnI Ser-23/24 reduces C-I interaction and
that this directly impacts thin filament activation and myofi-
bril relaxation kinetics in cardiac muscle. We also hypothe-
sized that the modulatory effects of cTnI phosphorylation
are greater at the submaximal Ca2þ levels present in cardi-
omyocytes during a cardiac twitch. To test this, rat ventric-
ular myofibrils were isolated and endogenous cTn was
exchanged with recombinant wild-type (WT) cTn 5 PKAhttp://dx.doi.org/10.1016/j.bpj.2014.07.027
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titin, we studied the specific role of cTnI phosphorylation
plays in myofilament tension regulation and relaxation
kinetics by exchanging the endogenous cTn of cardiac myo-
fibrils with recombinant cTn containing a constitutively
phosphorylated state cTnI (S23D/S24D-cTnI).
Using this combination of PKA treatment and the phos-
phomimetic cTnI mutant (S23D/S24D-cTnI), we found
that the Ca2þ sensitivity of contraction is reduced by phos-
phorylation of cTnI Ser-23/24, whereas the maximum ten-
sion production (TMAX) is maintained. The maximal (pCa
4.0) rate of Ca2þ-mediated activation and myofibril tension
generation (kACT) was slower with PKA treatment, although
the rate of tension redevelopment (kTR) following a release-
restretch cycle during steady-state activation was not,
suggesting that PKA treatment affects the maximal rate
of thin filament activation. The PKA treatment of WT
cTn or exchange of cTn containing S23D/S24D-cTnI
also made the early phase of relaxation (kREL,slow) faster
and this effect was greater at submaximal Ca2þ activation.
Interestingly, the larger, faster phase of relaxation (kREL,fast)
was unaffected. Steady-state fluorescence measurements
demonstrated that PKA phosphorylation of cTnI or
phosphomimetic S23D/S24D-cTnI resulted in reduced
Ca2þ-binding affinity (KCa) and C-I interaction (KC-I), as
previously reported (15,16). These results provide evidence
that PKA phosphorylation of cTnI can modulate the kinetics
of both thin filament activation and myofibril relaxation
and the effect may be greater at submaximal Ca2þ levels
seen in cardiomyocytes during twitch activity.MATERIAL AND METHODS
Proteins, cTnC labeling, cTnI phosphorylation,
and cTn complex reconstitution
Construction and expression of WT rat cTnC, cTnI, and cTnT in the pET24
vector has been previously described (17) (see the Supporting Material
for details). C35S-cTnC and S23D/S24D-cTnI were constructed by a
site-directed mutagenesis kit from WT cTnC and cTnI, respectively. The
C35S-cTnC mutation was introduced to allow site-specific attachment
of a fluorescent probe (IANBD ({N-[2-(iodoacetoxy)ethyl]-N-methyl}
amino-7-nitrobenz-2-oxa-1,3-diazole (Mw ¼ 406.14))) at C84 to monitor
Ca2þ binding to cTn as well as the C-I interaction. The labeling efficiency
was determined to be 90% using Bio-Rad protein assay (18,19). Purified
cTnI was phosphorylated by the catalytic subunit of PKA, using a cTnC
affinity column (20), and the phosphorylated product was designated as
pS23/pS24-cTnI. Whole cTn complexes were formed using rat cTnC
(WT or IANBD-cTnCC35S), rat cTnI (WT, pS23/pS24, or S23D/S24D),
and rat cTnT (WT) at a 1:1:1 molar ratio (21,22). The cTn complexes
with IANBD-cTnCC35S and/or pS23/pS24-cTnI forms were only used for
solution biochemistry measurements.cTn complexes exchange into myofibrils
cTn complexes (final concentration ~1.0 mg/ml) containing either WT
or S23D/S24D cTnI were passively exchanged into isolated myofibrils in
a buffer containing (in mM): 200 KCl, 20 MOPS, 5 MgCl2, 2 EGTA, 1DTT, and 4 ATP for overnight on a slow rocker at 4C. Following this, myo-
fibrils were washed twice for 30 min with gentle mixing in relaxing solution
containing 1 mg/ml bovine serum albumin to remove any nonspecifically
bound exogenous cTn.Solutions for myofibril mechanics
Solution composition was computed by an iterative algorithm that calcu-
lates the equilibrium concentration of ligands and ions based on published
affinity constants (23). Relaxing solutions contained (in mM): 80 MOPS,
15 EGTA, 1 Mg2þ, 5 MgATP, 83 Kþ, 52 Naþ, 15 creatine phosphate,
and 20 units/ml creatine phosphokinase, pH 7.0, solution ionic strength
was 170 mM. The inorganic Pi concentration determined by NMR
measurement was 0.5 mM (24). Experimental temperature was 15C. For
activation solutions, the Ca2þ level (expressed as pCa ¼ log [Ca2þ])
was set by adjusting with CaCl2. For PKA treatment, myofibrils were
exposed to 200 mL relaxing solution containing 100 units of the catalytic
subunit of PKA and 6 mM DTT for 45 min at 20C.SDS-PAGE and Western blots
To monitor the extent of exogenous cTn incorporation into myofibrils, we
used cTn in which cTnT contained a 9 amino acid myc-tag at the N-termi-
nus, similar to previous studies (25). The exchange efficiency was deter-
mined through Western blot analysis after the proteins were extracted by
SDS sample buffer and separated by 12.5% SDS PAGE. The presence of
the myc-tag allowed us to visibly separate the exchanged protein from
endogenous. Exchange efficiency was determined by calculating the
percent of myc-tagged cTnT (top band) and endogenous cTnT (bottom
band) present in the sample.Ethical approval and tissue preparation
All animal procedures were performed in accordance with the U.S. National
Institutes of Health Policy on Humane Care and Use of Laboratory Animals
and were approved by the University of Washington (UW) Institutional
Animal Care and Use Committee (IACUC). Rats were housed in the
Department of Comparative Medicine at UW and cared for in accordance
with UW IACUC procedures. Male, Sprague-Dawley rats (150–250 g)
were anesthetized with an intraperitoneal injection of pentobarbital
(50 mg/kg) after initial exposure to isoflurane (3–5% in oxygen). When
the animal had no reflexive response, the heart was rapidly excised and
dissected in oxygenated physiological salt solution containing (in mM):
100 NaCl, 2.5 KCl, 24 NaHCO3, 1 Na2HPO4, 1 MgSO4,7H2O, and 1
CaCl2 (26). Spliced left ventricles were demembranated for 24 h at 4
C
in relaxing solutions containing (in mM): 100 KCl, 9 MgCl2, 4 Na2ATP,
5 K2EGTA, 10 MOPS, 1% nonionic detergent Triton X-100, pH 7.0, and
50% v/v glycerol (8,27).Myofibril mechanics measurements
Single or small bundles of cardiac myofibrils were prepared from ventric-
ular tissue and experiments were performed as previously described (28)
(see the Supporting Material for details). The sarcomere length was initially
set at ~2.3 mm. Activation and relaxation data were collected at 15C and fit
with either single-exponential curves or linear coefficients as previously
described, and the solution change was complete in ~10 ms (28–30).
Briefly, the activation rate (kACT; with rapid increase in Ca
2þ) was estimated
from a single-exponential rise to a maximum. Once tension reached steady
state, a release-restretch protocol was performed to measure the time course
of tension redevelopment. A sudden decrease in length (20% of optimal
length) was imposed on the myofibrils, and after 25 ms of unloaded
shorting, myofibrils were rapidly stretched back to their original length.Biophysical Journal 107(5) 1196–1204
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to pCa 9.0. Relaxation rate for the early, slow phase (kREL,slow) was deter-
mined from the slope of a regression line fit to the tension trace, normalized
to the tension amplitude. The duration of the slow phase was measured from
the onset of solution change at the myofibril to the shoulder marking the
beginning of the fast phase. Transition from slow to rapid phase was
determined through multiple factors. An apparent change in the slope of
the data or a change in the signal/noise ratio was often apparent at the
transition. The subsequent fast phase of relaxation (kREL,fast) to baseline
(resting) tension was measured from a single exponential decay fitted to
the data. A t1/2 estimation was made in cases where the decay was not
well described by a single exponential, and this was converted to a rate
t ¼ ln (2)/t1/2.Steady-state fluorescence measurements
Steady-state fluorescent measurements have been previously described in
detail (31). All steady-state fluorescence measurements were taken using
a Perkin-Elmer LS50B luminescence spectrometer at 15C. IANBD fluo-
rescence was excited at 490 nm and monitored at ~530 nm. Protein buffer
solutions contained (in mM): 20 MOPS, 150 KCl, 3 MgCl2, 2 EGTA, and 1
DTT (pH 7.0). The fluorescence signal of 2 mL of IANBD cTnCC35S or
IANBD cTnC35S (0.6 mM) was monitored with the titration of microliter
amounts of cTnI (WT, pS23/pS24, or S23D/S24D) or Ca2þ in the presence
(100 mM) or absence of Ca2þ. The free Ca2þ concentration was calculated
using Maxchelator (32). The Ca2þ sensitivity of conformational changes
(pCa50, pCa value at half-maximal fluorescence signal change) were ob-
tained by fitting the binding curve with the sigmoid Hill equation as pre-
viously described (33). The reported values are the means of three to six
successive titrations.RESULTS
Recombinant cTn complex exchange profiles
and phosphorylation profile
Recombinant cTn complex containing WT or S23D/S24D-
cTnI were exchanged into rat ventricular myofibrils to
determine the effects of isometric tension development
and relaxation kinetics. To quantify the extent of the
exchange, cTn containing cTnT labeled at the N-terminus
with a c-myc tag was exchanged into myofibrils. Densitom-
etry analysis of Western blots using cTnT-specific anti-Biophysical Journal 107(5) 1196–1204bodies indicated that this procedure typically results in
over 90% endogenous cTn replacement by cTn containing
the c-myc tagged cTnT (Fig. 1 A), similar to the exchange
efficiencies reported by our group and others in myofibrils
and demembranated trabeculae (24,34). This suggests
that the exchange protocol was efficient and changes in con-
tractile parameters should be attributed to the exchanged
cTn containing either WT cTnI or cTnI phosphomimetic
variants.
WT-cTnI was phosphorylated by PKA using a cTnC
column. To quantify the extent of cTnI phosphorylation,
the phosphorylation profile was determined by Western
blot using antibodies of rabbit polyclonal to cTnI (phospho
S22 þ S23) and goat antirabbit IgG-HRP, whereas the
total amount of cTnI was determined using antibodies of
rabbit polyclonal lgG to cTnI (H170) and goat antirabbit
IgG-HRP (Fig. 1 B). These measurements suggested the
phosphorylation protocol was very efficient with 87% of
cTnI successfully phosphorylated.
Endogenous cTn in isolated myofibrils was passively
exchanged for recombinant rat cTn containing either WT-
cTnI or S23D/S24D-cTnI overnight, the myofibrils were
then washed with relaxing solution containing bovine serum
albumin twice. The extent of phosphorylation for cMyBP-C
and titin was not measured, however, it should be the
same for each group of WT-cTnI and S23D/S24D-cTnI
exchanged myofibrils, as these preparations were made
from the same hearts. For all WT-cTnI treated groups,
myofibril samples were divided into two aliquots, one
treated with PKA and the other with an equal amount of
buffer, for measurement of the kinetics of thin filament acti-
vation and myofibril relaxation. The extent of phosphory-
lation for cTnI in WT myofibrils (before PKA-treatment)
was related to the exchange efficiency. Because exchange
of recombinant cTn into rat myofibrils for replacing native
cTn was not 100% (but close to it), some small amount of
residual cTnI phosphorylation was likely present in every
exchange batch. Here, we measured the cTnI phosphoryla-
tion profile before and after PKA treatment in both nativeFIGURE 1 (A) Exchange efficiency of recom-
binant rat cardiac troponin complex (cTn) into rat
cardiac myofibrils. (B) PKA phosphorylation
profile for WT-cTnI using a cTnC column. (C).
PKA phosphorylation profile of cTnI for native
andWT-cTn exchanged myofibrils before and after
PKA treatment.
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endogenous cTnI phosphorylation levels in native myofi-
brils were ~40%, and the cTnI phosphorylation signal after
PKA treatment was highly increased, showing over 85%
cTnI was phosphorylated. Following exchange of recombi-
nant WT-cTn into native myofibrils, the phosphorylation
level of cTnI was almost completely eliminated, further
confirming the exchange protocol was nearly complete.
Similar to the native myofibrils, PKA treatment also dramat-
ically increased the cTnI phosphorylation signaling, result-
ing in over 85% cTnI phosphorylated.FIGURE 2 (A) Sample trace for a rat cardiac myofibril after exchanging
recombinant cTn complex. The inset is a close-up of a slow phase of relax-
ation. Contraction and relaxation kinetics parameter for rat cardiac myofi-
bril after exchanging recombinant rat WT cTn complex5 PKA treatment
at (B) maximal (pCa ¼ 4.0) and (C) submaximal (pCa ¼ 5.4) Ca2þ levels.
To see this figure in color, go online.Myofibril activation kinetics
Myofibrils exchanged with recombinant cTn complex con-
taining either WT or S23D/S24D cTnI were exposed to
continually flowing solutions that were rapidly switched
for step increases and decreases in [Ca2þ], from pCa 9.0
to either maximal (pCa 4.0) or submaximal [Ca2þ], and
finally back to 9.0. With this protocol, the magnitude and
rate of tension generation and relaxation at 15C were
then collected, as shown in an example tension trace in
Fig. 2 A. Table 1 and Fig. 2, B and C, summarize the tension
magnitude and kinetic parameters for rat ventricular myofi-
brils exchanged with cTn containing WT cTnI 5 PKA
treatment. The kinetic results of native rat ventricular myo-
fibrils are summarized in Table S1.
We first compared contraction during maximal (pCa 4.0)
Ca2þ activation. TMAX did not differ between untreated and
PKA-treated myofibrils (76 5 9 vs. 73 5 12 mN/mm2,
respectively) containing WT-cTnI, consistent with our pre-
vious results on the demembranated trabeculae (34). The
rate of tension rise with rapid switching from pCa 9.0
to 4.0 solution (kACT) includes the kinetic processes of
Ca2þ-dependent thin filament activation, myosin cross-
bridge binding, and subsequent development of tension.
kACT was 3.7 5 0.3 s
1 for untreated myofibrils and was
significantly slower (2.65 0.4 s1) for PKA-treated myofi-
brils. To differentiate between the cross-bridge versus thin
filament contributions to kACT, once activation was complete
(tension in steady state), we also measured the rate of
tension redevelopment (kTR) following rapid release and
restretch of myofibrils. The kTR protocol is thought to mea-
sure the rate of myosin cross-bridge attachment and subse-
quent tension generation (27), following myofibril release
and restretch, with Ca2þ binding to cTn and thin filament
activation in near steady state. The kTR (5.6 5 1.3 s
1)
was faster than kACT (3.7 5 0.3), suggesting the thin fila-
ment activation process may be rate limiting for rat cardiac
myofibrils at 15C, similar to what we have reported for
mouse cardiac myofibrils (24). Following PKA treatment,
kTR (5.8 5 1.3 s
1) did not differ from nontreated myofi-
brils. This suggests that the slowing of kACTwith PKA treat-
ment likely resulted from a slowing of the thin filament
activation process during maximal Ca2þ activation.In addition to maximal Ca2þ activation, it is important to
determine how the kinetics of contraction are affected by
PKA treatment during submaximal Ca2þ activations, which
is more reflective of what occurs during a cardiac twitch.
For our initial assessment, we chose a Ca2þ level (pCa 5.4
~4 mM), which was below the half-maximal (pCa50) acti-
vation of the rat ventricular myofibrils, producing 0.41
TMAX (30 5 4 mN/mm
2). In contrast to TMAX, tension
was lower (19 5 6 mN/mm2) in PKA-treated myofibrils
at pCa 5.4, reflecting the previously reported reduction inBiophysical Journal 107(5) 1196–1204
TABLE 1 Tension generation and relaxation parameters after recombinant rat WT cTn or rat cTn contained S23D/S24D-cTnI
exchange into rat ventricular myofibrils at 15C
Myofibril batches (n) pCa
Tension generation
kTR (s
1)
Relaxation
Slow phase Fast phase
Tmax (mN/mm
2) kACT (s
1) tREL,slow (ms) kREL,slow (s
1) kREL,fast (s
1)
WT (16) 4.0 765 9 3.7 5 0.3 5.65 1.3 855 8 0.9 5 0.2 185 3
(12) 5.4 305 4 1.6 5 0.2 3.45 0.6 94 5 14 2.1 5 0.3 175 2
WTþPKA (14) 4.0 735 12 2.65 0.4a 5.85 1.3 565 4a 1.75 0.3b 245 3b
(10) 5.4 19 5 6a 1.4 5 0.1 2.95 0.5 605 4a 7.15 2.1a 165 3
S23D/S24D (20) 4.0 61 5 5a 2.75 0.3a 7.15 0.4 655 5a 2.75 0.6b 225 3
(8) 4.8 465 13 3.1 5 0.4 7.25 0.4 555 5 4.5 5 0.5 235 2
(7) 5.2 265 6 3.0 5 0.4 6.75 0.4 495 7 6.1 5 1.9 185 2
(7) 5.4 17 5 3a 3.1 5 0.3b 6.5 5 0.4a 525 6a 6.15 1.6b 205 3
(7) 5.6 85 2 3.2 5 0.3 4.55 1.6 67 5 12 6.4 5 2.1 175 4
Values given are mean5 SE. Number in parentheses is number of myofibrils. ap < 0.05 vs. WT, and bp < 0.01 vs. WT.
1200 Rao et al.the Ca2þ sensitivity of tension that occurs with PKA treat-
ment (11). The contraction kinetics for these activations is
summarized in Fig. 2 C. At pCa 5.4, both kACT and kTR
were considerably slower than during maximal Ca2þ activa-
tions (no PKA treatment), as previously reported for mouse
cardiac myofibrils (24), demonstrating the Ca2þ sensitivity
of contraction kinetics. Furthermore, similar to maximal
Ca2þ activation, kACT was significantly slower than kTR,
again suggesting thin filament activation kinetics are
limiting to the rate of tension development. However, in
contrast to maximal Ca2þ activations, there was no differ-
ence in kACT between untreated and PKA-treated myofibrils
(1.6 5 0.2 vs. 1.4 5 0.1 s1, respectively). This suggests
that for activations with subsaturating levels of Ca2þ, the in-
fluence of PKA-mediated phosphorylation of myofilament
protein to attenuate the kinetics of thin filament activation
is reduced or eliminated. This will be discussed in more
detail below.Myofibril relaxation kinetics
Because b-adrenergic modulation of cardiac function also
includes elevated heart rate, faster relaxation is important
to ensure maintained or increased diastolic ventricular
filling. Thus, we also measured how the kinetics of relax-
ation are affected by PKA treatment at maximal and sub-
maximal Ca2þ levels. For myofibrils producing isometric
tension, rapid switching back to Ca2þ free solution (pCa
9.0) results in an early, slow phase of relaxation followed
by a more rapid (fast) phase back to baseline tension
(Fig. 2 A). The rate (kREL,slow) of slow phase relaxation
(0.9 5 0.2 s1), which is thought to be determined pri-
marily by the cross-bridge detachment rate (24,29,35–
38), was almost twice as fast for PKA-treated myofibrils
(1.7 5 0.3 s1). The duration (85 5 8 ms) of the slow
phase (tREL,slow) was also significantly shorter for PKA-
treated myofibrils (56 5 4 ms). Here, we also analyzed
the contribution of the slow phase relaxation, and found
that the contributions before and after PKA phosphoryla-Biophysical Journal 107(5) 1196–1204tion at pCa 4.0 were 6% and 10%, respectively. We pre-
viously demonstrated that tREL,slow is sensitive to the
properties of cTn and that a reduction in Ca2þ-binding af-
finity and/or C-I interaction can result in a shorter dura-
tion of the slow phase (24). The much larger, fast phase
of relaxation (kREL,fast) is thought to be reflective of
several sarcomere properties and also uneven relaxation
kinetics between sarcomeres in series (29,36–38). This
rate (18 5 3 s1) was also faster for PKA-treated myofi-
brils (24 5 3 s1).
During relaxation from contractions at pCa 5.4, kREL,slow
was >twofold faster (2.1 5 0.3 s1) than during maximal
Ca2þ activation, but tREL,slow of the slow phase (94 5
14 ms) and the fast phase rate kREL,fast (17 5 2 s
1) were
not significantly affected. Similar to pCa 4.0, PKA-treated
myofibrils had significantly reduced tREL,slow (60 5 4 ms)
at pCa 5.4 compared to nontreated myofibrils. Interestingly,
PKA treatment greatly increased kREL,slow at pCa 5.4 (7.15
2.1 s1) compared with nontreated myofibrils, whereas
kREL,fast was not affected (16 5 3 s
1). At pCa 5.4, the
contributions of slow phase relaxation before and after
PKA phosphorylation were 10% and 18%, respectively.
These data suggest the primary effect of PKA treatment
during submaximal Ca2þ activation is to reduce myofibril
tension and the slow phase of relaxation, which speeds
overall relaxation.Myofibril activation and relaxation kinetics
with S23D/S24D-cTnI
To determine the specific role of cTnI phosphorylation
(without phosphorylation of cMyBP-C or titin), we
exchanged cTn containing the phosphomimetic mutant
S23D/S24D-cTnI into myofibrils to study activation and
relaxation at maximal and submaximal Ca2þ concentra-
tions. S23D/S24D-cTnI has previously been demonstrated
to mimic the effect of PKA phosphorylation of cTnI at
Ser-23/24 both structurally and functionally (39,40). Ca2þ
levels were chosen to produce tensions that were <25%
PKA Effects on Myofilament Relaxation 1201(pCa 5.6), ~25% (pCa 5.4), ~50% (pCa 5.2), and ~75% (4.8)
of maximal (pCa 4.0) activated tension. The data of tension
magnitude and kinetics parameters are also summarized in
Table 1. Similar to PKA treatment, myofibrils containing
S23D/S24D-cTnI slowed the kinetics of maximal Ca2þ
(pCa 4.0) activation (2.7 5 0.3 s1) compared with WT
cTn exchanged myofibrils (3.75 0.3 s1), though the effect
was somewhat smaller in magnitude for kACT. Also similar,
kACT was significantly slower than kTR. Akin to the PKA-
treated myofibril, the kREL,slow (2.7 5 0.6 s
1) is signifi-
cantly faster and the tREL,slow (65 5 5 ms) is shorter in
the myofibrils containing S23D/S24D-cTnI compared with
WT cTn exchanged myofibrils, especially for submaximal
Ca2þ conditions. An example tension trace demonstrating
this is shown in Fig. 3. Interestingly, no clear changes
were detected in kREL,fast in the S23D/S24D-cTnI
exchanged myofibrils.FIGURE 4 Changes in the IANBD fluorescence emission intensity of (A)
cTnCC35S in complex with cTnTWT and cTnI variants with titration of Ca2þ
and (B) of cTnCC35S alone with titration of cTnI variants in the presence of
100 mM Ca2þ. To see this figure in color, go online.Steady-state fluorescence measurements
of KC-I and KCa
To determine the effects of PKA phosphorylation on KC-I
and KCa of cTn, in the absence of confounding influences
of other myofilament proteins, we performed steady-state
biochemical measurements with the fluoroprobe IANBD
attached at the C84 of cTnCC35SIANBD. IANBD, serves as
an environment-sensitive and sulfhydryl-reactive extrinsic
fluorophore, and has been used to label protein molecules
for studying the intramolecular interactions (18,31,41).
Fluorescence labeling at C84 reports on conformational
changes in NcTnC resulting from Ca2þ binding. We first
compared the Ca2þ-dependent conformational changes of
cTn containing either WT-cTnI, phosphorylated-cTnI
(pS23/pS24-cTnI), or S23D/S24D-cTnI. As shown in
Fig. 4 A, phosphorylation (pS23/pS24-cTnI) reduced
Ca2þ-binding affinity compared to the WT-cTn complex.FIGURE 3 Slow phase relaxation transient at submaximal Ca2þ level for
WT-cTn (black) and S23D/S24D-cTn (red) exchanged rat cardiac myofi-
brils. To see this figure in color, go online.The Ca2þ sensitivity of the fluorescence signal (reported
as pCa50) was shifted 0.31 pCa units, from 7.05 5
0.03 (WT-cTnI) to 6.74 5 0.03 (pS23/pS24-cTnI).
cTn containing S23D/S24D-cTnI also demonstrated a
similar right shift (pCa50 ¼ 6.77 5 0.03) compared to
WT-cTn.
C-I interaction plays a gate keeper role in translating
the Ca2þ signal to other myofilament proteins to initiate
cardiac muscle contraction. Binding of cTnI to cTnC
was measured by titrating labeled cTnCC35SIANBD with cTnI
variants in the presence of 100 mM Ca2þ. Fig. 4 B shows
the IANBD fluorescence change as the cTnI concentration
is increased up to 0.8 mM in solutions containing 0.6 mM
cTnCC35SIANBD. The lack of further change in the fluorescence
signal beyond 0.6 mM cTnI suggests a strong affinity of
cTnI for cTnC and that 1:1 binding of cTnC/cTnI was
achieved. Both the phosphorylated-cTnI (pS23/pS24-
cTnI) and the cTnI phosphomimetic (S23D/S24D-cTnI)
reduced C-I affinity compared to WT-cTnI. We are
currently studying the structural basis of how phosphory-
lation of cTnI influences C-I interaction and Ca2þBiophysical Journal 107(5) 1196–1204
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tions (42).DISCUSSION
It is well established that cTnI is phosphorylated by PKA at
sites Ser-23/24 during b-adrenergic stimulation, and that
this affects Ca2þ-mediated contraction of cardiac muscle.
Zhang et al. (11) demonstrated that PKA phosphorylation
of a cardiac skinned muscle results in decreased Ca2þ
sensitivity of muscle contraction, as well as an increased
rate of cardiac muscle relaxation. Kentish et al. (12) also
reported that PKA phosphorylation accelerated the myofi-
brillar relaxation rate, and suggest that this is due, at least
in part, to faster cross-bridge cycle kinetics. Both of these
studies used Diazo-2, a Ca2þ chelator, which does not
allow complete relaxation from maximal activation.
Although faster cross-bridge cycling was implicated as a
means to faster relaxation, there was no direct assessment
of cross-bridge detachment rate. Additionally, the role of
thin filament activation kinetics, which is modulated by
Ca2þ and cTnI phosphorylation, in accelerating cross-
bridge detachment and relaxation was not examined.
Here, we provide evidence that thin filament activation ki-
netics is affected by PKA-mediated phosphorylation of
cTnI (via a reduction in C-I interaction), that this can
slow the kinetics of both tension development and relaxa-
tion, and that this effect is larger at the submaximal levels
of Ca2þ that the heart operates during a cardiac twitch.
Comparisons of kACT vs. kTR allowed us to distinguish
thin filament activation kinetics (with activation defined
as the availability of strong myosin binding sites on F-actin
of the thin filament) from the rate of tension development
(24), although measures of the initial, slow phase of relax-
ation provide a putative measure of the rate of cross-bridge
detachment (35,43).
The lusitropic effect of PKA phosphorylation on cTnI at
Ser-23/24 appears to result from two functional mecha-
nisms: i), a decrease in the Ca2þ-binding affinity of cTnC
and subsequent interactions of cTnC with cTnI to reduce
the Ca2þ-dependent activation of thin filament (44,45) and
ii), an increase in cross-bridge cycling rate (12,44) that is
likely due to increasing the rate-limiting process, detach-
ment of myosin from actin. To study the role of cTnI-spe-
cific effects, separate from potential effects from other
myofilament proteins phosphorylated by PKA (cMyBP-C
and titin) (11–14), we compared contraction and relaxation
of myofibrils treated with PKAversus those exchanged with
recombinant cTn containing the phosphomimic S23D/
S24D-cTnI. Our solution biochemical measurements of
cTn-Ca2þ binding affinity and C-I interaction gave nearly
identical results with comparing PKA treatment versus the
phosphomimic, validating its use to study the role of
cTnI-specific effects of phosphorylation on the kinetics of
myofibril contraction and relaxation.Biophysical Journal 107(5) 1196–1204Contractile activation kinetics
To better understand how PKA phosphorylation affects thin
filament activation, we compared kACT and kTR as Ca
2þ was
varied. Here, kACT reflects the combined rate of Ca
2þ bind-
ing to cTn, subsequent changes in interaction between cTn
subunits that allow thin filament activation and tension
generation. In contrast, kTR reports the rate of myosin
cross-bridge attachment and subsequent tension generation
when Ca2þ binding to cTn and thin filament activation are
in or near steady state. We found that there is no difference
for TMAX between untreated and PKA-treated myofibrils
at maximal Ca2þ level (pCa 4.0), although tension was
reduced by PKA treatment at submaximal Ca2þ, consistent
with our previous findings in rat trabeculae (34), and with
other reports (11,12).
A believed-novel finding is that kTR was faster than kACT
at both maximal and submaximal Ca2þ levels. This result is
different from most previous studies (29,35,43), where no
difference between kACT and kTR has been reported. The
most likely explanation for this difference with previous
reports is the level of contaminant Pi in experimental solu-
tions. Most previous reports involved using the enzyme pu-
rine nucleoside phosphorylase with the substrate 7-methyl
guanosine (the phosphate mop), such that Pi contamination
was reduced to<5 mM, and the solutions were referred to as
Pi-free solutions. In our study, we did not use this phosphate
mop and NMR measurement of our solutions determined
that contaminant Pi was ~0.5 mM (24). This level of Pi
is closer to what is present in the heart. The presence of
Pi influences cross-bridge cycling specifically, without
affecting thin filament activation kinetics. We previously re-
ported (24) that under phosphate mop conditions there was
no difference between kACT and kTR at the maximal Ca
2þ
level. However, without this mop in activation solutions
(0.5 mM contaminant Pi), kACT was slower than kTR. Our
current results confirm those previous findings during
maximal Ca2þ activation, and extend them by demon-
strating a similar effect at submaximal levels of Ca2þ and
at maximal Ca2þ when cTnI is phosphorylated by PKA.Myofibril relaxation kinetics
Measurements of relaxation rates of myofibrils by rapid
solution switching can provide insights into the role of
cross-bridge dynamics in this process. The time course of
full tension relaxation following Ca2þ removal (pCa 9.0,
Fig. 2 A) is most often biphasic, beginning with an early,
slow phase of relaxation followed by a more rapid (fast)
relaxation phase. Here, we reported that kREL,slow was accel-
erated at the submaximal Ca2þ level, even without cTnI
phosphorylation. This result is different from previous re-
ports, where this rate did not differ between relaxations
from maximal or submaximal Ca2þ activation (35,43,46).
Relaxation is a complicated process, involving Ca2þ
PKA Effects on Myofilament Relaxation 1203removal from cTnC and the effect of its loss and cross-
bridge detachment on thin-filament deactivation. The rate
and duration of the slow phase are very sensitive to the con-
ditions that affect cross-bridge kinetics, such as temperature,
muscle fiber type (myosin isoform), mechanical perturba-
tion, and chemical interventions. During submaximal
Ca2þ activations, we might expect the initial phase of relax-
ation to be faster than during maximal activation because
there is less Ca2þ binding to thin filaments at any given
time. Thus, when myosins detach, it is easier for the thin
filament to become deactivated. This is especially true for
cardiac muscle, where myosin binding has been shown to
enhance Ca2þ binding to the thin filament. Furthermore,
the presence of Pi (0.5 mM Pi in our study) should exacer-
bate this effect, as it results in a reduction of the tension
(strain) bearing cross-bridges. This may accelerate the
detachment of myosin cross-bridges from the thin filament,
thus contributing to an increase in the slow phase of
relaxation.
Both kTR and kREL,slow have commonly been used as a
reflection of the cross-bridge cycling rate and/or the rate
of cross-bridge detachment (35,43,47). However, it is impor-
tant to remember the differences in conditions during these
two measurements. For example, kTR is measured when
Ca2þ in activation solutions is constant and Ca2þ binding
to cTn is in a relative steady state. However, kREL,slow is
measured following the abrupt removal of Ca2þ from the
system. Thus, the amount of Ca2þ bound to the thin filament
is more dynamic and is reduced at a rate determined by the
Ca2þ dissociation rate (koff) of cTn. The change in bound
Ca2þ is likely most dramatic at the beginning of the relaxa-
tion phase, when the gradient of Ca2þ bound (to cTn) versus
that in solution is highest. Additionally, Ca2þ koff may be
further increased as cross-bridges start to detach (48) at
the beginning of relaxation. As such, it is difficult to make
strong correlations between kTR vs. kREL,slow as a measure
of cross-bridge cycling or detachment kinetics.
Similar to most previous findings for rodent cardiac
muscle, we found that PKA phosphorylation of cTnI re-
duces the Ca2þ sensitivity of tension, and speeds overall
relaxation. However, Walker et al. (49) reported that PKA
phosphorylation does not change cross-bridge kinetics in
human cardiac myofibrils. The reason for this difference
may be due to the different myosin isoforms in human
and rat cardiac myofibrils. Another possible reason is the
inorganic Pi concentration of solutions. The Walker study
did not report the Pi concentration, however, in an earlier
report, their Pi concentration is <5 mM. Perhaps more
interesting is our finding that the modulatory effect of
cTnI phosphorylation on myofibril relaxation is greater at
the submaximal Ca2þ and that this is correlated with a
reduction in C-I interaction. Thus, it may be that conditions
that reduce C-I interaction (here either reduce Ca2þ or cTnI
phosphorylation) result in reduced contractile activation, a
more rapid deactivation of the thin filament when Ca2þ isremoved and a more rapid initiation of the relaxation
process.CONCLUSION
The most significant findings of the current study are i),
the Ca2þ sensitivity of tension is decreased by PKA phos-
phorylation, although the maximal tension production is
maintained, as previously reported (34); ii), the phosphory-
lation of cTnI, rather than that of cMyBP-C and titin, is
responsible for the reduction of slow phase relaxation,
thus speeding overall relaxation; and iii), PKA phosphoryla-
tion of cTnI decreases C-I interaction (as well as the binding
affinity of Ca2þ to cTnC). These findings suggest a connec-
tion between C-I interaction and the kinetics of thin filament
activation, tension development, and the initial phase of
myofibril relaxation. Thus, the degree of C-I interaction
may act as a regulator that is modulated by changes in
Ca2þ and cTn phosphorylation during b-adrenergic stimula-
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